High-dose ara-C in older adults with acute leukemia.

Abstract

The concept of high-dose ara-C (HIDAC) was introduced 15 years ago. Phase I studies established a maximum tolerated dose of 3 g/m2, given every 12 hours for 12 doses. Because dermatologic, gastrointestinal, and central nervous system toxicities were dose-limiting in patients over age 50, a reduction from the maximal dose was suggested. Initial studies with refractory or resistant acute myelogenous leukemia (AML), with or without anthracyclines, demonstrated a significant antileukemic effect of HIDAC, with about 60 percent of patients achieving a complete response. Studies by our group and others have established that older patients can be successfully treated with HIDAC, probably with some added benefit in combining dose-intensive regimens.

• Authors: R H Herzig
• Journal: Leukemia (Leukemia) Vol. 10 Suppl 1 Pg. S10-1 (Apr 1996) ISSN: 0887-6924 [Print] England
• PMID: 8618461 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Cytarabine

Topics

• Age Factors
• Aged
• Antimetabolites, Antineoplastic (adverse effects, therapeutic use)
• Controlled Clinical Trials as Topic
• Cytarabine (adverse effects, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Middle Aged
• Multicenter Studies as Topic
• Remission Induction